Related Experiment Video
Updated: Nov 16, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Sarcomere mutation negative hypertrophic cardiomyopathy is associated with ageing and obesity
Alejandro E de Feria1, Andrew E Kott2, Jason R Becker3,4
1Division of Cardiology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Insights
Hypertrophic cardiomyopathy (HCM) patients without sarcomere mutations are often older and more obese. Further research is needed to understand the roles of aging and obesity in this condition.
Area of Science:
- Cardiology
- Genetics
- Medical Research
Background:
- A significant portion of hypertrophic cardiomyopathy (HCM) patients lack identified sarcomere gene mutations.
- The underlying causes of asymmetric myocardial hypertrophy in mutation-negative HCM remain unclear.
Purpose of the Study:
- To investigate differences in clinical phenotypes between HCM patients with and without sarcomere mutations.
- To identify potential contributing factors to HCM in the absence of sarcomere mutations.
Main Methods:
- Retrospective analysis of 127 HCM probands who underwent genetic testing.
- Collection of medical history, three-generation family history, and clinical phenotyping.
- Screening using clinically available HCM genetic testing panels.
Main Results:
- HCM patients with pathogenic sarcomere mutations were more likely to have a family history (66% vs 17%) and were diagnosed younger (32 vs 51 years).
- HCM patients without sarcomere mutations showed higher rates of obesity (BSA p=0.003, BMI p=0.04) and left ventricular outflow tract obstruction (p=0.0483).
Conclusions:
- Sarcomere mutation-negative HCM is associated with older age at presentation and increased obesity.
- The influence of aging and obesity on asymmetric myocardial hypertrophy requires further investigation.
Background:
Despite advances in our understanding of the genetic causes of hypertrophic cardiomyopathy (HCM), a large portion of this patient population do not carry sarcomere gene mutations when screened. It remains largely unknown why patients without sarcomere mutations develop asymmetric myocardial hypertrophy.
Methods:
We performed a retrospective analysis of probands with HCM who underwent genetic testing to determine if clinical phenotypes were different depending on sarcomere mutation status. A medical history, three generation family history and clinical phenotyping were performed on 127 probands with HCM. Genetic screening was performed using clinically available HCM genetic testing panels.
Results:
We found that probands with HCM with pathogenic sarcomere mutations were over three times more likely to have a family history of HCM (66% vs 17%, p<0.0001) and were diagnosed with HCM at a much younger age (32 vs 51 years old, p<0.0001). In contrast, probands with HCM without sarcomere mutations were significantly more obese (body surface area p=0.003, body mass index p=0.04 adjusted for age) and were more likely to present with left ventricular outflow tract obstruction (p=0.0483).
Conclusion:
Patients with sarcomere mutation negative HCM present at an older age and are more obese compared with patients with sarcomere mutation positive HCM. The role of ageing and obesity in asymmetric myocardial hypertrophy warrants further investigation.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure II: Pathophysiology

